SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward

被引:19
|
作者
Iserson, Kenneth, V [1 ]
机构
[1] Univ Arizona, Dept Emergency Med, Tucson, AZ 85721 USA
关键词
COVID-19; SARS-CoV-2; virus; vaccines; vaccine testing; immunization; CHALLENGE; INFECTION; EFFICACY;
D O I
10.1017/S096318012000047X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The world awaits a SARS-CoV-2 virus (i.e., COVID-19 disease) vaccine to keep the populace healthy, fully reopen their economies, and return their social and healthcare systems to "normal." Vaccine safety and efficacy requires meticulous testing and oversight; this paper describes how despite grandiose public statements, the current vaccine development, testing, and production methods may prove to be ethically dubious, medically dangerous, and socially volatile. The basic moral concern is the potential danger to the health of human test subjects and, eventually, many vaccine recipients. This is further complicated by economic and political pressures to reduce government oversight on rushed vaccine testing and production, nationalistic distribution goals, and failure to plan for the widespread immunization needed to produce global herd immunity. As this paper asserts, the public must be better informed to assess promises about the novel vaccines being produced and to tolerate delays and uncertainty.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [1] Overview of SARS-CoV-2 and COVID-19 Vaccine
    Alhaibil, Nada Abdullah
    BAHRAIN MEDICAL BULLETIN, 2021, 43 (02) : 511 - 515
  • [2] Analysis of SARS-CoV-2 vaccine against COVID-19
    Kazuyori, Taisuke
    Sato, Akihito
    Morimoto, Yasuhiro
    Ito, Akihiko
    Kuwano, Kazuyoshi
    RESPIROLOGY, 2023, 28 : 202 - 203
  • [3] SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward
    Bansal, N.
    Raturi, M.
    Bansal, Y.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2022, 29 (02) : 161 - 163
  • [4] COVID-19 Vaccine Development and the Way Forward
    Arora, Narendra Kumar
    Das, Manoja Kumar
    INDIAN JOURNAL OF PUBLIC HEALTH, 2020, 64 : 108 - 111
  • [5] A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals
    Chavda, Vivek P.
    Feehan, Jack
    Apostolopoulos, Vasso
    VACCINES, 2021, 9 (06)
  • [6] SARS-CoV-2 and COVID-19
    Sheng, Wang-Huei
    Ko, Wen-Chien
    Huang, Yhu-Chering
    Hsueh, Po-Ren
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (03) : 363 - 364
  • [7] Measuring and Promoting SARS-CoV-2 Vaccine Equity: Development of a COVID-19 Vaccine Equity Index
    Pressman, Alice R.
    Lockhart, Stephen H.
    Shen, Zijun
    Azar, Kristen M. J.
    HEALTH EQUITY, 2021, 5 (01) : 476 - 483
  • [8] FrontierTherapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
    Sheikhshahrokh, Amirhossein
    Ranjbar, Reza
    Saeidi, Elnaz
    Safarpoor Dehkordi, Farhad
    Heiat, Mohammad
    Ghasemi-Dehkordi, Payam
    Goodarzi, Hamed
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2020, 49 : 18 - 29
  • [9] Dermatomyositis in Association With SARS-CoV-2 Infection or COVID-19 Vaccine
    Diaz-Menindez, Maximiliano
    Sullivan, Megan M.
    Wang, Benjamin
    Majithia, Vikas
    Abril, Andy
    Butendieck Jr, Ronald R.
    Ball, Colleen T.
    Berianu, Florentina
    ARTHRITIS CARE & RESEARCH, 2024, 76 (01) : 98 - 104
  • [10] mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
    Kackos, Christina M.
    Surman, Sherri L.
    Jones, Bart G.
    Sealy, Robert E.
    Jeevan, Trushar
    Davitt, Christopher J. H.
    Pustylnikov, Sergei
    Darling, Tamarand L.
    Boon, Adrianus C. M.
    Hurwitz, Julia L.
    Samsa, Marcelo M.
    Webby, Richard J.
    MICROBIOLOGY SPECTRUM, 2023, 11 (01):